STF Management LP Has $715,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

STF Management LP cut its holdings in Moderna, Inc. (NASDAQ:MRNA) by 4.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,017 shares of the company’s stock after selling 252 shares during the quarter. STF Management LP’s holdings in Moderna were worth $715,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Quadrant Capital Group LLC grew its position in shares of Moderna by 7.5% in the 4th quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock valued at $266,000 after purchasing an additional 187 shares during the period. Ontario Teachers Pension Plan Board acquired a new position in Moderna during the 4th quarter worth approximately $1,358,000. Hobbs Group Advisors LLC acquired a new position in Moderna during the 4th quarter worth approximately $664,000. Illinois Municipal Retirement Fund boosted its position in Moderna by 22.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock worth $5,519,000 after acquiring an additional 9,360 shares during the last quarter. Finally, Swedbank AB acquired a new position in Moderna during the 1st quarter worth approximately $3,315,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Up 1.3 %

MRNA opened at $69.17 on Tuesday. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The stock’s fifty day simple moving average is $94.12 and its 200 day simple moving average is $111.72. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The stock has a market cap of $26.51 billion, a PE ratio of -4.41 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the business earned ($3.62) EPS. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. As a group, research analysts expect that Moderna, Inc. will post -9.52 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on MRNA. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday. Royal Bank of Canada reduced their price target on Moderna from $90.00 to $75.00 and set a “sector perform” rating for the company in a research report on Friday. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Finally, Hsbc Global Res raised Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average price target of $103.93.

Insider Activity at Moderna

In related news, President Stephen Hoge sold 15,000 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00. Following the sale, the president now owns 1,442,089 shares in the company, valued at approximately $174,665,819.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Moderna news, President Stephen Hoge sold 15,000 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the transaction, the president now owns 1,442,089 shares in the company, valued at approximately $174,665,819.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,158 shares of company stock worth $11,167,312. Company insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.